NASDAQ:ASPH

Finance·Health·Investments·NASDAQ:ASPH·News

AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results

Ascentage Pharma’s U.S.-listed shares closed at $21.01 Friday, up 1.69%, after hitting a 52-week low of $18.56 earlier in the week. The rebound followed the release of new ASCO 2026 clinical data on olverembatinib, lisaftoclax, and alrizomadlin. Nasdaq is closed for Memorial Day on Monday. The stock remains about 57% below its 52-week high.

May 23, 2026

Xero Shares Plunge 62% Amid Tech Sell-Off, Analysts Bullish on 87% Upside
May 29, 2026, 8:21 PM EDT. Xero Ltd (ASX: XRO) shares have fallen 62% from a $196.52 peak in June 2025, pressured by a broader tech sector sell-off linked to AI disruption fears and prior overvaluation concerns. Currently trading at $74.16, Xero is down 34% year-to-date. Despite recent losses, 14 of 15 analysts rate Xero shares a buy or strong buy, with an average 12-month target price implying a 76% gain to $130.81, and some forecasts projecting up to 218% upside. The company's recurring subscription revenue offers predictable cash flow, underpinned by high customer retention from accounting and payroll services. Growth prospects include expansion in the UK and US markets, automation enhancements, and product suite diversification. Recent FY26 results underscore 31% revenue growth and 18% EBITDA increase, reinforcing long-term investment appeal.